{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:21Z","timestamp":1788985341694,"version":"build-2803163510"},"reference-count":83,"publisher":"Informa UK Limited","issue":"16","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.2217\/imt-2022-0109","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T09:22:21Z","timestamp":1668417741000},"page":"1279-1290","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Deucravacitinib in Moderate-To-Severe Psoriasis"],"prefix":"10.1080","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-7791","authenticated-orcid":false,"given":"Alan","family":"Vu","sequence":"first","affiliation":[{"name":"Department of Dermatology,\u00a0Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Dermatology,\u00a0Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Dermatology,\u00a0Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.688"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S290309"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.04.042"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.906"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.017"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70359-2"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.026"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.12.005"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13469"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19314"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.022"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00948"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00554-4"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.283"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"issue":"9","key":"e_1_3_3_34_1","first-page":"3214","article-title":"Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity","volume":"16","author":"Strobl B","year":"2011","unstructured":"Strobl B , StoiberD , SexlV , MuellerM. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. (Landmark Ed.)16(9), 3214\u20133232 (2011).","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"2","key":"e_1_3_3_35_1","first-page":"859","article-title":"SAT0226 A first-in-human study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2","volume":"76","author":"Catlett I","year":"2017","unstructured":"Catlett I , ArasU , LiuYet al. SAT0226 A first-in-human study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Ann. Rheum. Dis.76(Suppl. 2), 859 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00948"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01698"},{"key":"e_1_3_3_40_1","volume-title":"29th European Academy of Dermatology and Venereology Virtual Congress.","author":"Chimalakonda A","year":"2020","unstructured":"Chimalakonda A , SinghalS , DockensRet al. BMS-986165, an oral, selective tyrosine kinase 2 inhibitor: overview of pharmacokinetics in healthy volunteers, including ADME, food, pH effects, and drug\u2013drug interactions [P1420]. Presented at: 29th European Academy of Dermatology and Venereology Virtual Congress.Lugano, Switzerland, 29\u201331 October 2020."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_3_3_42_1","unstructured":"Safety study of BMS-986165 in healthy subjects and to treat psoriasis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02534636"},{"key":"e_1_3_3_43_1","unstructured":"Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02931838"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_3_45_1","unstructured":"Effectiveness and safety of BMS-986165 compared to placebo and active comparator in participants with psoriasis (POETYK-PSO-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03624127"},{"key":"e_1_3_3_46_1","volume-title":"30th European Academy of Dermatology and Venereology Congress.","author":"Warren RB","year":"2021","unstructured":"Warren RB , ArmstrongA , GooderhamMet al. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Presented at: 30th European Academy of Dermatology and Venereology Congress.Lugano, Switzerland, 29 September\u20132 October 2021."},{"key":"e_1_3_3_47_1","volume-title":"30th European Academy of Dermatology and Venereology Congress.","author":"Korman N","year":"2021","unstructured":"Korman N . Deucravacitnib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: onset of action in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Presented at: 30th European Academy of Dermatology and Venereology Congress.Lugano, Switzerland, 29 September\u20132 October 2021."},{"key":"e_1_3_3_48_1","volume-title":"30th European Academy of Dermatology and Venereology Congress.","author":"Tha\u00e7i D","year":"2021","unstructured":"Tha\u00e7i D . P1407 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: integrated laboratory parameter results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Presented at: 30th European Academy of Dermatology and Venereology Congress.Lugano, Switzerland, 29 September\u20132 October 2021."},{"key":"e_1_3_3_49_1","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis (POETYK-PSO-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03611751"},{"key":"e_1_3_3_50_1","unstructured":"An investigational study to evaluate experimental medication BMS-986165 in Japanese participants with moderate-to-severe psoriasis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03924427"},{"key":"e_1_3_3_51_1","unstructured":"Long-term study that measures the safety and efficacy of deucravacitinib (BMS-986165) in participants with psoriasis (POETYK PSO-LTE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04036435"},{"key":"e_1_3_3_52_1","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo in participants with plaque psoriasis (POETYK-PSO-3) in Mainland China Taiwan and South Korea (POETYK-PSO-3). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04167462"},{"key":"e_1_3_3_53_1","unstructured":"A study to evaluate the drug levels efficacy and safety of BMS-986165 in adolescent participants with moderate to severe plaque psoriasis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04772079"},{"key":"e_1_3_3_54_1","unstructured":"Efficacy and safety of BMS-986165 compared with placebo in participants with active psoriatic arthritis (PsA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03881059"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_3_3_56_1","unstructured":"A study to determine the efficacy and safety of deucravacitinib compared with placebo in participants with active psoriatic arthritis (PsA) who are na\u00efve to biologic disease modifying anti-rheumatic drugs or had previously received TNF\u03b1 inhibitor treatment. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04908189"},{"key":"e_1_3_3_57_1","unstructured":"A study to evaluate efficacy and safety of BMS-986165 in participants with active discoid and\/or subacute cutaneous lupus erythematosus (DLE\/SCLE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04857034"},{"key":"e_1_3_3_58_1","unstructured":"An investigational study to evaluate the safety and effectiveness of BMS-986165 with background treatment in participants with lupus nephritis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03943147"},{"key":"e_1_3_3_59_1","unstructured":"An investigational study of experimental medication BMS-986165 in healthy participants to study electrocardiogram effects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03541564"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1056"},{"key":"e_1_3_3_61_1","unstructured":"An investigational study to evaluate BMS-986165 in participants with systemic lupus erythematosus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03252587"},{"key":"e_1_3_3_62_1","unstructured":"Long-term safety and efficacy study of deucravacitinib in participants with systemic lupus erythematosus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03920267"},{"key":"e_1_3_3_63_1","unstructured":"Safety and efficacy of deucravacitinib in participants with moderate to severe ulcerative colitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03934216"},{"key":"e_1_3_3_64_1","unstructured":"A study of the safety efficacy and biomarker response of BMS-986165 in participants with moderate to severe ulcerative colitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04613518"},{"key":"e_1_3_3_65_1","unstructured":"A study to evaluate the long-term safety and efficacy of BMS-986165 in participants with Crohn\u2019s disease or ulcerative colitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04877990"},{"key":"e_1_3_3_66_1","unstructured":"Sotyktu (deucravacitinib) package insert. Bristol Myers Squibb NJ USA (2022)."},{"key":"e_1_3_3_67_1","unstructured":"Otezla (apremilast) package insert. Amgen Inc. CA USA (2021)."},{"key":"e_1_3_3_68_1","unstructured":"Enbrel (etanercept) package insert. Immunex Corporation CA USA (2021)."},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_3_3_70_1","unstructured":"Remicade (infliximab) package insert. Janssen Biotech Inc. PA USA (2021)."},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.017"},{"key":"e_1_3_3_72_1","unstructured":"Humira (adalimumab) package insert. AbbVie Inc. IL USA (2021)."},{"key":"e_1_3_3_73_1","unstructured":"Cimzia (certolizumab pegol) package insert. UCB Inc. GA USA (2019)."},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41384"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2022-0109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:17:46Z","timestamp":1715980666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2022-0109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":83,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.2217\/imt-2022-0109"],"URL":"https:\/\/doi.org\/10.2217\/imt-2022-0109","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}